# Table 2 miR-10b-5p: copies per microliter of serum according to clinicopathological features

Feature Cohort A (Italy) Cohort B (USA)
Average copies/μL ± SD Average copies/μL ± SD
(n = number of patients) (n = number of patients)
Tumor size (pT) pT1 108.7 ± 78.0 (n = 19) 98.6 ± 47.3 (n = 28)
pT2 97.3 ± 55.9 (n = 6) 143.4 ± 70.3 (n = 27)
pT3 / 75.0 ± 11.9 (n = 4)
Lymph node involvement (pN) pN0 88.7 ± 37.2 (n = 18) 101.2 ± 54.6 (n = 35)
pN1-2-3 113.3 ± 89.4 (n = 7) 145.2 ± 70.8 (n = 23)
Stage I 82.9 ± 28.5 (n = 14) 91.3 ± 45.9 (n = 23)
II 107.7 ± 79.9 (n = 10) 128.0 ± 61.8 (n = 25)
III 134.0 (n = 1) 130.5 ± 60.2 (n = 8)
IV / 242.2 ± 110.3 (n = 2)
Grade I 80.8 ± 36.5 (n = 5) 114.9 ± 43.2 (n = 11)
II 112.7 ± 88.6 (n = 18) 91.2 ± 58.8 (n = 13)
III 105.0 ± 54.3 (n = 5) 136.0 ± 74.81 (n = 34)
ER/PR status ER+/PR+ 142.1 ± 98.44 (n = 17) 115.0 ± 60.1 (n = 35)
ER-/PR- 74.0 (n = 1) 131.9 ± 89.4 (n = 16)
HER2/neu receptor Positive 103.7 ± 80.8 (n = 3) 112.9 ± 65.5 (n = 11)
Negative 115.8 ± 88.4 (n = 25) 145.8 ± 75.0 (n = 44)
Triple Negatives ER-/PR-/HER2- 74.0 (n = 1) 117.8 ± 90.2 (n = 9)
Others 118.2 ± 85.61 (n = 27) 121.5 ± 63.36 (n = 49)
1. ER estrogen receptor, PR progesterone receptor, HER2/neu human epidermal growth factor receptor 2
{"ft_lang_label":"__label__en","ft_lang_prob":0.6593451,"math_prob":0.8315611,"size":1234,"snap":"2021-31-2021-39","text_gpt3_token_len":668,"char_repetition_ratio":0.15528455,"word_repetition_ratio":0.007380074,"special_character_ratio":0.70097244,"punctuation_ratio":0.19130434,"nsfw_num_words":0,"has_unicode_error":false,"math_prob_llama3":0.9856832,"pos_list":[0,1,2],"im_url_duplicate_count":[null,1,null],"WARC_HEADER":"{\"WARC-Type\":\"response\",\"WARC-Date\":\"2021-09-21T16:17:27Z\",\"WARC-Record-ID\":\"<urn:uuid:466d6ad3-7d0a-4085-91d9-a7d9f747baf7>\",\"Content-Length\":\"134666\",\"Content-Type\":\"application/http; msgtype=response\",\"WARC-Warcinfo-ID\":\"<urn:uuid:8ebe04f5-1f23-4748-b0eb-e0e037362216>\",\"WARC-Concurrent-To\":\"<urn:uuid:0a897c84-1ae4-4a93-bb3e-66e06a666a42>\",\"WARC-IP-Address\":\"199.232.64.95\",\"WARC-Target-URI\":\"https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-015-0037-0/tables/2\",\"WARC-Payload-Digest\":\"sha1:TALVPD457E56ZSXLBC5HFCVPRJIXP5VU\",\"WARC-Block-Digest\":\"sha1:LT2NVGNV4742CVMH53I6OUV2OFDY5Q5P\",\"WARC-Identified-Payload-Type\":\"text/html\",\"warc_filename\":\"/cc_download/warc_2021/CC-MAIN-2021-39/CC-MAIN-2021-39_segments_1631780057225.57_warc_CC-MAIN-20210921161350-20210921191350-00421.warc.gz\"}"}